2015 ADX Header

Cambridge Healthtech Institute’s Eighth Annual
Predictive Cancer Biomarkers
Pushing Discovery to Advance Clinical Translation
August 18-19, 2015 | Capital Hilton | Washington, DC

Cancer biomarkers have become an essential component of patient care. With discovery efforts ongoing, the next phase towards translation will involve validation and demonstration of clinical utility. Cambridge Healthtech Institute's Eighth Annual Predictive Cancer Biomarkers will focus on the steps needed to manage the new treatment paradigm from treating clinical symptoms to targeting genomic pathways. Focus will be given to the use of circulating tumor material to follow patients peripherally, both with known metastatic disease and post-surgery. Throughout the event, top cancer researchers will present their latest discoveries, case studies, and best practices to decrease late-stage diagnosis and improve patient outcomes.

Preliminary Agenda


Clinical NGS of Hematological Malignancies

Jennifer Morrissette, Ph.D., Scientific Director, Clinical Cytogenetics Laboratory; Clinical Director, Center for Personalized Diagnostics (CPD), University of Pennsylvania Perelman School of Medicine

Predictive Biomarkers for Targeted Cancer Therapy

Baolin Zhang, Ph.D., Senior Investigator, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration


Circulating microRNAs and other Nucleic Acids in Treatment Monitoring

Anton Wellstein, M.D., Ph.D., Professor, Oncology, Georgetown University


The Department of Veterans Affairs Precision Oncology Program

Louis Fiore, M.D., Executive Director, MAVERIC, Boston VA Healthcare System

Enrolling Patients in Clinical Trials Based on NGS Data

P. Mickey Williams, Ph.D. (contractor), Director, Molecular Characterization Laboratory (aka MoCha), Frederick National Laboratory for Cancer Research

Qiagen Bioinformatics Automated Multimodal, High-Multiplex, Quantitative Molecular Platform Solution for Complicated Companion Diagnostics

Lily Kong, Senior Director, Assay Development, Assay Development, Qiagen


Utility of Implementing Clinical NGS Assays as Standard of Care in Oncology

Helen Fernandes, Ph.D., Director, Molecular Pathology, Pathology & Laboratory Medicine, Weill Cornell Medical College

Development and Implementation of Clinical NGS Testing: Assay Development and Informatic Challenges

Robert D. Daber, Ph.D., Director, Research and Development and Sequencing Operations, Bio-Reference Laboratories

The Medical Exome and Constitutional NGS Studies

Avni B. Santani, Ph.D., Assistant Professor, Clinical Pathology, University of Pennsylvania School of Medicine; Scientific Director, Molecular Genetics Laboratory, The Children's Hospital of Philadelphia

Monitoring the Cancer Genome in Plasma Using Circulating Tumor DNA

Nitzan Rosenfeld, Ph.D., Senior Group Leader, CRUK-CI, University of Cambridge; CSO, Inivata, Ltd.

For more details on the conference, please contact:
Samantha Lewis
Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: slewis@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Joe Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

2014 Brochure

2014 Brochure 

Premier Sponsor

ThermoFisher Scientific logo 

Related Products